Vacunas (English Edition)最新文献

Vaccination against the COVID-19 pandemic, decreed by the WHO in 2020, has shown in the initial trials an admissible efficacy for the scientific community, but with many doubts and concerns for the communities, developing the phenomenon known as vaccine hesitancy.

Objective

To understand the factors associated with the intention or rejection of vaccination against COVID-19 in the city of Popayán in the year 2022.

Methodology

Cross-sectional descriptive-analytical study, carried out between August 2021 and March 2022; with a non-probabilistic sampling, for convenience, with a sample size of 993 people; A questionnaire-type survey was applied in person and virtually to know the intention of vaccination, knowledge and perceptions.

Results

The surveyed population was characterized as 56.19% female, 49.24% between 18 and 28 years old; 23.16% state that they do not intend to be vaccinated against COVID-19, the main reasons being: not being well informed 56.29%, ineffective vaccine 54.8% and that the vaccine weakens the immune system 27,5%; as well as the low confidence with the Vaccination Plan and with the pharmaceutical companies that produce the vaccine.

Conclusion

The intention to vaccinate against COVID-19 is determined not only by the technical-administrative dynamics of the immunization program and the health system, variables of the context and the perception of risk, add up to explain the vaccination processes.

Background

The SARS-CoV-2 pandemic affected the school-aged population because of the disease itself and due to the measures applied for prevention and control of the infection. The aim of the study was to evaluate the effect of population-based vaccination against COVID-19 on the incidence of infection in school settings.

Material and methods

A retrospective descriptive study of COVID-19 cases and school outbreaks was carried out at the province level. Students, teachers and staff from different educational stages of the schools were included. The outcome measure was the incidence according to educational stage, case profile and clinic during the first of the academic year 2020/2021 versus the same period 2021/2022.

Results

The total incidence of SARS-CoV-2 in classrooms was 2470 cases per 100,000 population in the first trimester of the academic year 2020/2021 and 2720 cases per 100,000 population in the same period 2021/2022. The number of reported school outbreaks was 7 times higher in this second period; and the risk of infection in classrooms over 12 years of age (students and teachers) was reduced by 43.1% (vaccinated in high percentage).

Conclusions

This study shows a reduction in transmission of SARS-CoV-2 infection in students of higher educational stages (secondary and high school) during the first of the academic year 2021/2022 (group with high vaccination coverage at the beginning of the period) compared to the previous school year (without vaccination).

Background

COVID-19 is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The characteristics of this infectious disease vary from a country to another and from one peak to the next. The aim of the present study was to describe the COVID-19 patients hospitalized in Kermanshah, a city in the west of Iran, in the third peak of the disease and to identify in-hospital mortality determinants in this disease.

Methods

In this retrospective study, the clinical and demographic characteristics, laboratory findings, prescribed treatments and outcome of all COVID-19 patients (definitive, suspected, and probable) were collected from the medical records department of Farabi Hospital affiliated with Kermanshah University of Medical Sciences, Kermanshah, Iran from 22 October to 20 November 2020.

Results

In total, 665 COVID-19 patients (265 females and 400 males, mean age: 58.7 years) were enrolled, including 479 confirmed (72%), 156 probable (23.5%), and 30 suspected cases (4.5%). About 84% of the patients presented with low oxygen saturation levels. The most common comorbidities were hypertension (15%), diabetes (10%), and cardiovascular disease (3%). The median (IQR) length of hospital stay was 6 (4–8) and 7 (2–14) day in discharged and deceased patients, respectively. Eighty-two out of 655 patients admitted to the hospital and 39 of the 60 patients admitted to the ICU died. In total, in-hospital mortality rate was 12.33%. Regarding lab variables, in the adjusted model, no significant difference was observed between discharged and deceased patients.The results of multivariable logistic regression showed that each one-unit increase in oxygen saturation (SPO₂) increased the odds of survival by 0.88 times (95% CI 0.78–0.99, p = 0.043). Moreover, each one-day increase in the length of ICU stay reduced the odds of mortality by 0.49 times (95% CI 0.26–0.95, p = 0.035).

Conclusion

Hospitalized COVID-19 patients were generally more ill during the third peak so that about 85% of the patients had SPO₂ < 93%. The in-hospital mortality rate was also high. Demographic and paraclinical variables (except SPO₂ level) were not suitable predictors of mortality.

The outbreak of SARS-CoV-2, an etiologic agent of the COVID-19 pandemic disease in late December 2019 has left the whole world aghast with huge health and economic losses. Due to a lack of specific knowledge and understanding at the initial stages, an unprecedented rise in COVID-19 cases has been recorded globally. Various preventive measures and strategies were implemented, however, for the radical control of SARS-CoV-2 infections; it seems that the only effective way to control the ongoing infections is large-scale vaccination. So far, WHO has approved 11 vaccines for emergency use namely Pfizer/BioNTech, Oxford/Astra Zeneca, Johnson and Johnson, Moderna, Covilo, Novavax, Covovax, Spikevax, Can Sino, Comirnaty, and Coronavac while five other needs approval. The worldwide vaccination dataset reveals that 65.7% of the world population has received their first dose of the COVID-19 vaccine. As a consequence of the proactive implementation of India's vaccination program, a historical milestone of administering over 1.9 billion doses of COVID-19 vaccines have been achieved on 19th May 2022. This review summarizes the different types of traditional and modern vaccine designing strategies with an emphasis on COVID-19. Moreover, the review highlights the status of vaccines for COVID-19 approved in India which includes both indigenous and non-indigenous vaccines. The present article also encompasses vaccine designing and developmental strategies, efficacy, safety profile and usage among the population, and the efficacy of modern vaccines over traditional ones.

Traditionally, PCV (pneumococcal conjugate vaccine) was prepared by the coupling of aldehyde-activated polysaccharide, with a carrier protein via NaCNBH3 (sodium cyanoborohydride) mediated reductive amination in water. However, the reaction is very slow and may take up to several days, which is a significant burden for pharmaceutical companies. Here we report the detailed reaction process of the reductive amination of structurally reassigned serotype 31 polysaccharide and cross reacting material (CRM197) in an organic solvent (N,N-dimethylformamide, DMF) by using STAB (sodium triacetoxyborohydride). The product has been characterized by size exclusion chromatography, nuclear magnetic resonance and transmission electron microscopy. Compared with the traditional method, the reaction can finish within hours and elicited a comparable immune response. The new strategy has the potential of being applied in the preparation of next-generation polysaccharide conjugate vaccines.

The Respiratory Syncytial Virus (RSV) is the cause of acute respiratory pathologies (bronchiolitis and pneumonia) that occurs preferably as epidemic in the winter months. RSV is a good vaccine candidate since as a virus it has shown genetic and antigenic stability, most infections are self-limited and the only natural reservoir is humans. According to epidemiological data, there are three target populations that require different approaches for the RSV vaccine: naive children < 4–6 months, children > 6 months, and >65 years. Multiple vaccine platforms based on the preF protein are currently being studied, although the use of long-lived monoclonal antibodies must be considered in the first year of life. In the child population, beyond this period, attenuated vaccines probably play a relevant role, since they expose the complete viral particle to the immune system and induce a broad-spectrum neutralising antibody response. In the population > 65 years of age, the need to use a subunit vaccine with an adjuvant that stimulates the immune response or mRNA vaccines is evident. The future in the prevention of RSV infection and disease in the human population will be based on the use of monoclonal antibodies and vaccines adapted to each age group.

Introduction

In Spain, influenza vaccination is available in companies free of charge for their workers. Despite this, vaccination coverage against influenza is very low in these groups.

Objectives

The aim of this work is to know the reasons for acceptance of influenza vaccination in a working population.

Methods

During the 2021–2022 influenza vaccination campaign, we conducted a survey of two groups of workers at the automobile factories of RENAULT ESPAÑA S.A. in the cities of Valladolid and Palencia (Spain). The first group (NV) was formed by 304 (33.5%) workers who did not receive the influenza vaccine in the previous season. The second (V) was formed by 604 workers (66.5%) who had been vaccinated against influenza at least the previous season. In the NV group, they were asked the reasons why they did not get vaccinated the previous season and if they did so in 2021–2022. In group V, only the reasons for continuing to be vaccinated were asked.

Results

In NV, the main reason for avoiding vaccination in the previous season was the lack of perception of the severity of the influenza infection (74.7%), and 31.6% and 29.0% of them decided to get vaccinated during the 2021–2022 season due to the fear of co-infection of SARS-CoV-2 and influenza and medical recommendations respectively. The 83.5% of group V responded that the reason for getting vaccinated in 2021–2022 was their adherence to vaccination.

Conclusions

The results show that medical recommendation is the best tool to vaccinate workers against influenza and make them adhere to it. Also, the fear to co-infection of COVID-19 and flu was a frequent reason for getting vaccinated, above all in NV.

Introduction

The burden of influenza in the paediatric population is often underestimated by healthcare professionals and the general population, mainly due to poor perception of its clinical importance at the individual level and its health impact at the healthcare level. The aim of this review was to collect data on the burden of paediatric influenza in Spain and to compare them with data of countries where vaccination strategies for healthy paediatric populations have been implemented.

Methods

We collected data on the burden of paediatric influenza in Spain through a systematic search of literature published between 2016–2021 (PRISMA methodology). We conducted a review of reports from the Spanish Influenza Surveillance System (SVGE) (2010–2011 to 2019–2020) and of international reports (from Canada, Finland, USA, and UK) through a systematic (2016–2021) and pragmatic search.

Results

1366 articles were obtained from the systematic searches by country; 26 met the inclusion criteria. According to the SVGE (Spain's Influenza Surveillance System), those < 15 years have the highest incidence of influenza per 100,000 population (cumulative-mean rate: 9457.9) compared to those ≥ 15 years (2285.6), and percentage of admission to the Paediatric Intensive Care Unit (PICU) greater than those > 65 years (mean: 29.1% vs. 17.5%). Hospitalisation of severe cases per 100,000 population in children aged 0–4 years and those > 65 years is similar (median: 20.2 vs. 28.4). Those aged < 15 years have a higher incidence rate per 100,000 population (213.3), in contrast to those aged 15–64 years (21.9) and those aged ≥ 65 years (65.2). In countries with paediatric vaccination programmes (USA, Finland, and UK) the burden of influenza in children is reduced by 40%–74%, whereas 50%-93.5-% of cases presenting to the ED, hospitalised, admitted to PICU, or dying from influenza are unvaccinated.

Conclusions

The burden of paediatric influenza in Spain includes a significant number of hospitalisations and PICU admissions and justifies the vaccination strategy recommended by the WHO since 2012. In countries with this recommendation, the vaccinated paediatric population is better protected against severe forms of influenza and potential benefits for reducing the burden of paediatric influenza in Spain can be extracted from their data.